Aprotinin: Pharmacological benefits and safety concerns

Andrea Székely, Daniel J. Lex, B. Merkely

Research output: Chapter in Book/Report/Conference proceedingChapter

1 Citation (Scopus)

Abstract

In cardiac surgery, perioperative blood transfusion carries considerable risk of complications and increases resource utilization. Antifibrinolytics, particularly aprotinin, have been used effectively to reduce bleeding and transfusion needs. In 2008, the manufacturer withdrew aprotinin from the market due to the discontinued “Blood conservation using antifibrinolytics in a Randomized Trial” (Brat) study, which showed an increased mortality associated with the use of aprotinin.

Original languageEnglish
Title of host publicationReducing Mortality in the Perioperative Period
PublisherSpringer International Publishing
Pages125-130
Number of pages6
ISBN (Print)9783319021867, 9783319021850
DOIs
Publication statusPublished - Jan 1 2014

Fingerprint

Aprotinin
Antifibrinolytic Agents
Pharmacology
Safety
Blood Transfusion
Thoracic Surgery
Hemorrhage
Mortality

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Székely, A., Lex, D. J., & Merkely, B. (2014). Aprotinin: Pharmacological benefits and safety concerns. In Reducing Mortality in the Perioperative Period (pp. 125-130). Springer International Publishing. https://doi.org/10.1007/978-3-319-02186-7_16

Aprotinin : Pharmacological benefits and safety concerns. / Székely, Andrea; Lex, Daniel J.; Merkely, B.

Reducing Mortality in the Perioperative Period. Springer International Publishing, 2014. p. 125-130.

Research output: Chapter in Book/Report/Conference proceedingChapter

Székely, A, Lex, DJ & Merkely, B 2014, Aprotinin: Pharmacological benefits and safety concerns. in Reducing Mortality in the Perioperative Period. Springer International Publishing, pp. 125-130. https://doi.org/10.1007/978-3-319-02186-7_16
Székely A, Lex DJ, Merkely B. Aprotinin: Pharmacological benefits and safety concerns. In Reducing Mortality in the Perioperative Period. Springer International Publishing. 2014. p. 125-130 https://doi.org/10.1007/978-3-319-02186-7_16
Székely, Andrea ; Lex, Daniel J. ; Merkely, B. / Aprotinin : Pharmacological benefits and safety concerns. Reducing Mortality in the Perioperative Period. Springer International Publishing, 2014. pp. 125-130
@inbook{1be953bf5ca3480b8967cd63341784ab,
title = "Aprotinin: Pharmacological benefits and safety concerns",
abstract = "In cardiac surgery, perioperative blood transfusion carries considerable risk of complications and increases resource utilization. Antifibrinolytics, particularly aprotinin, have been used effectively to reduce bleeding and transfusion needs. In 2008, the manufacturer withdrew aprotinin from the market due to the discontinued “Blood conservation using antifibrinolytics in a Randomized Trial” (Brat) study, which showed an increased mortality associated with the use of aprotinin.",
author = "Andrea Sz{\'e}kely and Lex, {Daniel J.} and B. Merkely",
year = "2014",
month = "1",
day = "1",
doi = "10.1007/978-3-319-02186-7_16",
language = "English",
isbn = "9783319021867",
pages = "125--130",
booktitle = "Reducing Mortality in the Perioperative Period",
publisher = "Springer International Publishing",

}

TY - CHAP

T1 - Aprotinin

T2 - Pharmacological benefits and safety concerns

AU - Székely, Andrea

AU - Lex, Daniel J.

AU - Merkely, B.

PY - 2014/1/1

Y1 - 2014/1/1

N2 - In cardiac surgery, perioperative blood transfusion carries considerable risk of complications and increases resource utilization. Antifibrinolytics, particularly aprotinin, have been used effectively to reduce bleeding and transfusion needs. In 2008, the manufacturer withdrew aprotinin from the market due to the discontinued “Blood conservation using antifibrinolytics in a Randomized Trial” (Brat) study, which showed an increased mortality associated with the use of aprotinin.

AB - In cardiac surgery, perioperative blood transfusion carries considerable risk of complications and increases resource utilization. Antifibrinolytics, particularly aprotinin, have been used effectively to reduce bleeding and transfusion needs. In 2008, the manufacturer withdrew aprotinin from the market due to the discontinued “Blood conservation using antifibrinolytics in a Randomized Trial” (Brat) study, which showed an increased mortality associated with the use of aprotinin.

UR - http://www.scopus.com/inward/record.url?scp=84955741879&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84955741879&partnerID=8YFLogxK

U2 - 10.1007/978-3-319-02186-7_16

DO - 10.1007/978-3-319-02186-7_16

M3 - Chapter

AN - SCOPUS:84955741879

SN - 9783319021867

SN - 9783319021850

SP - 125

EP - 130

BT - Reducing Mortality in the Perioperative Period

PB - Springer International Publishing

ER -